Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3726
Editas Medicine
EDIT
$402M
| $566K | ﹤0.01% |
276,262
+89,212
| +48% | +$258K |
2016 Q3
37 quarters
|
|
3727
Global X Defense Tech ETF
SHLD
$6.73B
| $562K | ﹤0.01% |
+8,679
| New | +$571K |
2025 Q4
0 quarters
|
|
3728
Farmers & Merchants Bancorp
FMAO
$489M
| $561K | ﹤0.01% |
22,679
+1,839
| +9% | +$45.9K |
2023 Q3
9 quarters
|
|
3729
Maravai LifeSciences
MRVI
$1.18B
| $560K | ﹤0.01% |
172,281
+5,057
| +3% | +$17K |
2022 Q1
15 quarters
|
|
3730
Savers
SVV
$1.42B
| $560K | ﹤0.01% |
59,909
+5,183
| +9% | +$53.3K |
2023 Q2
10 quarters
|
|
|
SMC
3731
Summit Midstream
SMC
$425M
| $559K | ﹤0.01% |
20,955
+4,508
| +27% | +$107K |
2024 Q3
5 quarters
|
|
3732
Security National Financial
SNFCA
$236M
| $558K | ﹤0.01% |
65,044
+3,850
| +6% | +$31.1K |
2020 Q2
22 quarters
|
|
3733
Byrna Technologies
BYRN
$81.4M
| $557K | ﹤0.01% |
33,199
+5,744
| +21% | +$112K |
2024 Q2
6 quarters
|
|
|
FRMI
3734
Fermi Inc
FRMI
$2.58B
| $556K | ﹤0.01% |
+69,536
| New | +$1.36M |
2025 Q4
0 quarters
|
|
3735
Jack in the Box
JACK
$239M
| $556K | ﹤0.01% |
29,351
-69,901
| -70% | -$1.26M |
2013 Q2
50 quarters
|
|
|
IA
3736
Innovative Solutions & Support
IA
$340M
| $556K | ﹤0.01% |
29,335
+25,363
| +639% | +$289K |
2025 Q3
1 quarter
|
|
3737
Lloyds Banking Group
LYG
$79.1B
| $555K | ﹤0.01% |
104,700
+102,650
| +5,007% | +$497K |
2015 Q2
42 quarters
|
|
|
KLAR
3738
Klarna Group
KLAR
$4.74B
| $554K | ﹤0.01% |
19,147
+16,347
| +584% | +$561K |
2025 Q3
1 quarter
|
|
3739
Red River Bancshares
RRBI
$681M
| $552K | ﹤0.01% |
7,722
-519
| -6% | -$35.5K |
2019 Q2
26 quarters
|
|
3740
Organogenesis Holdings
ORGO
$171M
| $551K | ﹤0.01% |
106,407
+8,697
| +9% | +$42.1K |
2019 Q1
27 quarters
|
|
3741
Inogen
INGN
$158M
| $551K | ﹤0.01% |
81,980
+3,515
| +4% | +$26.4K |
2014 Q1
47 quarters
|
|
|
NAGE
3742
Niagen Bioscience
NAGE
$221M
| $549K | ﹤0.01% |
86,385
+7,802
| +10% | +$54.3K |
2024 Q2
6 quarters
|
|
3743
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$4.02B
| $549K | ﹤0.01% |
5,894
+2,742
| +87% | +$255K |
2013 Q2
50 quarters
|
|
3744
Nathan's Famous
NATH
$416M
| $549K | ﹤0.01% |
5,864
+1,557
| +36% | +$157K |
2022 Q3
13 quarters
|
|
3745
Capital Bancorp
CBNK
$659M
| $548K | ﹤0.01% |
19,449
+2,963
| +18% | +$85K |
2018 Q4
28 quarters
|
|
3746
Achieve Life Sciences
ACHV
$746M
| $547K | ﹤0.01% |
110,032
+110,031
| +11,003,100% | +$480K |
2024 Q2
6 quarters
|
|
|
MITT
3747
TPG Mortgage Investment Trust
MITT
$183M
| $546K | ﹤0.01% |
64,106
+15,867
| +33% | +$124K |
2024 Q2
6 quarters
|
|
3748
Structure Therapeutics
GPCR
$1.97B
| $545K | ﹤0.01% |
7,833
+4,060
| +108% | +$166K |
2023 Q2
10 quarters
|
|
3749
Citizens & Northern Corp
CZNC
$460M
| $544K | ﹤0.01% |
26,947
+774
| +3% | +$15.4K |
2016 Q1
39 quarters
|
|
3750
Hyster-Yale Materials Handling
HY
$560M
| $543K | ﹤0.01% |
18,280
+1,449
| +9% | +$47.8K |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.